News

Anup Patel, MD, pediatric epileptologist at Nationwide Children’s Hospital and leader within the Pediatric Epilepsy Research Consortium, discusses evolving AI-driven initiatives, Lennox-Gastaut syndrome research priorities, and future directions in pediatric epilepsy care.

Sara Cuccurullo, MD, chair, vice president, and medical director, Hackensack Meridian JFK Johnson Rehabilitation Institute, discussed emerging evidence supporting structured cardiovascular rehabilitation after stroke and ongoing efforts to expand access through potential Medicare policy changes.

The chief medical executive at Marcus Neuroscience Institute discussed the evolving role of AI, advanced imaging, and precision therapeutics in neurology presented at Baptist Health’s 2026 Brain & Spine Symposium. [WATCH TIME: 5 minutes]

The FDA's acceptance and priority review of levacetylleucine for ataxia-telangiectasia positions the therapy to potentially become the first approved treatment for the rare neurodegenerative disorder.

The registered nurse at the University of Miami and the president of the IOMSN discussed advice for younger colleagues, misconceptions about neurology nursing, and more. [WATCH TIME: 10 minutes]

Experts debate how to sequence new gMG therapies, manage seronegative and special populations, and close biomarker and access gaps.

The professor of psychiatry at the UCLA discussed postmortem findings suggesting that locus coeruleus neuron loss may be a more consistent feature of narcolepsy than hypocretin deficiency.

New RESTORE-FA results show DT-216P2 improved balance and fatigue within 4 weeks, with tolerable safety.

FDA Priority Review of asundexian marks a key regulatory milestone for factor XIa inhibition in secondary stroke prevention following positive phase 3 OCEANIC-STROKE results.

From exercise and lifestyle medicine to neuromodulation and vagus nerve stimulation, Andrew Abdou, DO, discusses emerging approaches that may help stroke patients continue recovery beyond traditional timelines.

New findings suggest that patients with obstructive sleep apnea and excessive daytime sleepiness exhibit distinct endotypic traits that may influence disease severity and symptom expression.

Armin Jewell, MD, neurologist and epilepsy specialist at Allina Health Brain and Spine Institute, discusses the clinical implementation of the Zeto One point-of-care EEG headset and its potential role in improving seizure assessment and neurologic care access in community settings.

Two newly published studies highlighted both the phase 3 efficacy data and biologic rationale supporting AD109 as a potential oral treatment option for obstructive sleep apnea.

Here's some of what is coming soon to NeurologyLive® this week.

The assistant professor of neurology and ophthalmology at NYU Grossman School of Medicine discussed findings presented at AAN 2026 on the use of optical coherence tomography in pediatric MS. [WATCH TIME: 8 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is glymphatic system for Parkinson!

Kelsey Jensen, MD, a movement disorders neurologist at Allina Health, discussed Parkinson disease diagnosis, deep brain stimulation candidacy, treatment personalization, and ongoing unmet needs in PD care and research.

Karen Lynch, MD, MRCPI, senior global medical director at Sanofi, discusses how delayed diagnosis in CIDP can contribute to irreversible nerve damage, long-term disability, and reduced functional recovery. [WATCH TIME: 3 minutes]

Neurology News Network for the week ending May 16th, 2026. [WATCH TIME: 5 minutes]

The registered nurse at the University of Miami and the president of the IOMSN shared their thoughts on the unique demands of nursing in neurology, with a particular focus on their experience in multiple sclerosis nursing. [WATCH TIME: 6 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 15, 2026.

At AAN 2026, the professor of neurology at the University of South Florida discussed findings from the phase 3 NIMBLE trial assessing cemdisiran in generalized myasthenia gravis. [WATCH TIME: 5 minutes]

The professor of cognitive neuroscience and imaging at the University of Western Ontario, Canada, detailed new research using the Creyos platform and machine learning to develop a rapid, scalable cognitive screener designed to identify early signs of cognitive decline and dementia risk.

The professor of neurology and director of the Division of Movement Disorders at the University of Alabama at Birmingham discussed 3-year data on AMT-130 and its potential as a disease-modifying gene therapy for Huntington disease. [WATCH TIME: 3 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Scott Grossman, MD. [LISTEN TIME: 13 minutes]

Data from the phase 2 CELIA study of diranersen will be presented at the 2026 Alzheimer’s Association International Conference (AAIC) 2026, held July 12-15, in London, United Kingdom.

Phase 3 AFFINITY DUCHENNE data showed that investigational RGX-202 achieved significant microdystrophin expression and correlated functional improvements in Duchenne muscular dystrophy, supporting plans for accelerated FDA approval.

In honor of Stroke Awareness Month, neurologist Firas Bounni, MD, discussed how advanced neuroimaging can guide thrombectomy decision-making beyond standard treatment windows.